RadarScreener › AGEN

AGEN

AGENUS INC
Nasdaq · Biological Products, (No Diagnostic Substances) · EDGAR filings (CIK 1098972) · 11 signals · 1 setups · updated Aug 16, 2026

What the filings say Pressure ▼

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.

Radar 82 (high attention) · dilution pressure high · listing risk low · governance risk elevated · runway 1.7 mo · strongest signal: Runway < 6 months (Jun 30, 2026)

What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

82Radar · attention score (0–100)
81Dilution pressure · financing + balance sheet
0Listing risk · exchange standards
48Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Forced-raise setup Pressure ▼ strength 0.95

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (negative equity, runway < 6 months) coexists with live selling machinery (atm program, shelf effective, shelf filed). Base case is a discounted raise; the question is when, not if.

Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
ATM programNegative equityRunway < 6 monthsShelf effectiveShelf filed

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on AGEN
Alerts
One email the morning AGEN files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for AGEN back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 985 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$18.7Mcash + short-term investments as of Jun 30, 2026
1.7 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])
$-199.1Mstockholders' equity as of Jun 30, 2026
$135.4Mpublic float (10-K cover)
45.0Mshares outstanding as of Aug 4, 2026 · was 41.6M May 7, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Aug 13, 2026· Officer/director change 8-K Item 5.02 filed 2026-08-13 (accepted 21:30 ET) filing 24
Aug 12, 2026· Form 4 burst 7 Form 4 filings in 30 days filing 15
Aug 11, 2026· Officer/director change 8-K Item 5.02 filed 2026-08-11 (accepted 16:30 ET) filing 23
Aug 7, 2026 ATM program “atm” language in S-3 (S-3) filed 2026-08-07 filing 34
Aug 7, 2026 Shelf filed S-3 filed 2026-08-07 filing 32
Aug 7, 2026 Going-concern language “going concern periodic” language in 10-Q (10-Q) filed 2026-08-07 filing 25
Jul 27, 2026 Shelf effective EFFECT notice 2026-07-27 filing 21
Jul 20, 2026 Shelf filed S-3 filed 2026-07-20 filing 35
Jun 30, 2026 Runway < 6 months ~1.7 months runway: liquidity $18,738,000 as of 2026-06-30, burn $136,163,250/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing 47
Jun 30, 2026 Negative equity Stockholders' equity $-199,075,000 as of 2026-06-30 filing 31
Jun 30, 2026 Cash < current liabilities Liquidity $18,738,000 vs current liabilities $231,820,000 filing 21

Other forced raise setups

VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans